Article Sidebar

Submitted
May 30, 2020
Accepted
Feb 7, 2021
Published
Mar 3, 2021
Download
PDF
Statistic
Read Counter : 640 Download : 1623

Main Article Content

Abstract

Background: Patients with liver cirrhosis are at a high risk of drug interactions due to the use of multi-drug combination regimens. Objectives: This study analyzed potential drug-drug interactions in the liver cirrhosis patients at Gatot Soebroto Army Hospital, Jakarta in 2016. Material and Methods: This study employed an observational-cross sectional design with retrospective data collection of liver cirrhosis patients' medical records. The data of potential drug-drug interactions were identified using Drug Interaction Facts 2012 including the mechanism type, the severity and the onset of drug interactions. Results: As many as 88% of the liver cirrhosis patients experienced potential drug-drug interactions with a total of 35 cases. The highest proportions of the cases were found in the pharmacokinetic mechanism by approximately 25 cases (71.43%), minor severity comprising 29 cases (82.86%) and rapid onset by 19 cases (54.29%). The highest potential drug-drug interactions were furosemide-propranolol combination in 16 cases (45.72%). Conclusions: The high incidence of potential drug interactions in patients with liver cirrhosis requires high vigilance and close monitoring of all health professionals in achieving optimal therapeutic outcomes for the patients.

Keywords

potential drug-drug interactions Drug Interaction Facts liver chirrosis

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Author Biographies

Annisa Farida Muti, Universitas Pembangunan Nasional “Veteran” Jakarta,

Pharmacy Program, Faculty of Medicine, Universitas Pembangunan Nasional “Veteran” Jakarta, Indonesia.

Chanica Anindya, Institut Sains dan Teknologi Nasional, Jakarta.

Pharmacy Program, Faculty of Pharmacy, Institut Sains dan Teknologi Nasional, Jakarta, Indonesia.

How to Cite
Muti, A. F., & Anindya, C. (2021). Analysis of Potential Drug-drug Interactions in Liver Cirrhosis Patients: Analisis Interaksi Obat-obat Potensial pada Pasien Sirosis Hati. Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (e-Journal), 7(1), 17-28. https://doi.org/10.22487/j24428744.2021.v7.i1.15148

References

  1. Abubakar AR, Chedi BAZ, Mohammed KG, Haque M. (2015). Drug Interaction and Its Implication in Clinical Practice and Personalized Medicine. National Journal of Physiology, Pharmacy and Pharmacology, 5(5), pp.343-49. http://dx.doi.org/10.5455/njppp.2015.5.2005201557
  2. Bacon BR. (2012). Cirrhosis and Its Complications. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J (Eds.), Harrison’s Principles of Internal Medicine. 18th edition. Volume 2. New York: McGraw-Hill. pp. 2592-602.
  3. Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. (2007). Hospitalisations and Emergency Department Visits due to Drug–Drug Interactions: A Literature Review. Pharmacoepidemiol Drug Saf, 16(6), pp.641–51. https://doi.org/10.1002/pds.1351
  4. Bista D, Saha A, Mishra P, Palaian S, Shankar PR. (2009). Impact of Educational Intervention on The Pattern and Incidence of Potential Drug-drug Interactions in Nepal. Pharm Pract (Granada). 7(4), pp.242-47. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134843/
  5. European Association for The Study of The Liver. (2010). EASL Clinical Practice Guidelines on The Management of Ascites, Spontaneous Bacterial Peritonitis, and Hepatorenal Syndrome in Cirrhosis. Journal of Hepatology, 53, pp.397-417. https://doi.org/10.1016/j.jhep.2010.05.004
  6. Ekawati H, Tungggul AP, Trisnowati BR. (2006). Pengaruh Visitasi Farmasis terhadap Potensi Interaksi Obat pada Pasien Lanjut Usia Rawat Inap di Bangsal Dahlia RSUD. Prof. Dr. Margono Soekarjo. Majalah Farmasi Indonesia. 17(4), pp.199-203.
  7. Farida Y, Andayani TM, Ratnasari N. (2014). Analisis Penggunaan Obat pada Komplikasi Sirosis Hati. Jurnal Manajemen dan Pelayanan Farmasi, 4(2), pp.77-84. https://doi.org/10.22146/jmpf.270
  8. Firth J, Jones D, Newton JL. (2009). Chronic Liver Disease In An Ageing Population. Age Ageing. 38(1), pp.11-8. https://doi.org/10.1093/ageing/afn242
  9. Franz CC, Egger S, Born C, Ritz Bravo AE, Krahenbuhl S. (2012). Potential Drug-Drug Interactions and Adverse Drug Reactions in Patients with Liver Cirrhosis. Eur J Clin Pharmacol, 68, pp.179-188. https://doi.org/10.1007/s00228-011-1105-5
  10. Hartshorn EA, Tatro DS. (2009). Principles of Drug Interactions. In: Tatro DS (Eds.), Drug Interaction Facts. California: Wolters Kluwel Health Inc.
  11. Herfindal ET, Gourley DR. (2000). Textbook of Therapeutic Drug and Disease Management. 7th edition. Philadelphia: A Wolter Kluwer. pp. 617-31.
  12. Kusumobroto HO. (2007). Sirosis Hati. Dalam: Sulaiman HA, Akbar HN, Lesmana LA, Noer HMS (Eds.), Buku Ajar Ilmu Penyakit Hati. Edisi Pertama. Jakarta: Jayabadi (pp. 335-345).
  13. Lindseth GN. (2005). Gangguan Hati, Kandung Empedu, dan Pankreas. In: Pendit BU, Hartanto H, Wulansari P, Susi N, Mahanani DA (Eds.), Patofisiologi: Konsep Klinis Proses-proses Penyakit. Edisi 6. Volume 1. Jakarta: Penerbit Buku Kedokteran EGC (pp. 472-511).
  14. Lovena A, Miro S, Efrida. (2017). Karakteristik Pasien Sirosis Hati di RSUP Dr. M. Djamil Padang. Jurnal Kesehatan Andalas. 6(1), pp.5-12. https://doi.org/10.25077/jka.v6i1.636
  15. Patasik YZ, Waleleng BJ, Wantania F. (2015). Profil Pasien Sirosis Hati yang Dirawat Inap di RSUP Prof. Dr. D. Kandou Manado Periode Agustus 2012 sampai Agustus 2014. Jurnal e-Clinic (eCl). 3(1), pp.342-7. https://doi.org/10.35790/ecl.3.1.2015.6841
  16. Reiberger T, Mandorfer M. (2017). Beta Adrenergic Blockade and Decompensated Cirrhosis. J Hepatol. 66(4), pp.849–59. https://doi.org/10.1016/j.jhep.2016.11.001
  17. Runyon BA. (2012). Management of Adult Patients with Ascites Due to Cirrhosis: Update 2012. https://www.aasld.org/sites/default/files/2019-06/141020_Guideline_Ascites_4UFb_2015.pdf
  18. Saksana RA, Bayupurnama P, Indrarti F, Ratnasari N, Maduseno S, Triwikatmani C et al. (2012). Correlation between the Severity of Liver Cirrhosis (Chil-Pugh Score) and QTc Interval Prolongation. The Indonesian Journal of Gastroenterology Hepatology and Digestive Endoscopy. 13(3). https://doi.org/10.24871/1332012157-160
  19. Saragih GG, Waleleng BJ, Haroen H. (2016). Gambaran Gangguan Hemostasis pada Penderita Sirosis Hati yang Dirawat di RSUP Prof. Dr. R. D. Kandou periode Agustus 2013-Agustus 2015. Jurnal e-Clinic (eCl), 4(1), pp.128-33. https://doi.org/10.35790/ecl.4.1.2016.10945
  20. Sari A, Wahyono D, Raharjo B. (2012). Identifikasi Potensi Interaksi Obat pada Pasien Rawat Inap Penyakit Dalam Di RSUD Prof. Dr. Margono Soekarjo Purwokerto dengan Metode Observasional Retrospektif Periode November 2009-Januari 2010. Jurnal Ilmiah Kefarmasian. 2(2), pp.195-203. http://dx.doi.org/10.12928/pharmaciana.v2i2.669.g508.
  21. Sease JM. (2011). Portal Hypertension and Cirrhosis. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Well BG, Posey LM (Eds.), Pharmacotheraphy: A Patophysiologic Approach. 8th edition. New York: The McGraw_Hill Companies Inc. (pp. 639-57).
  22. Sherry L, Murphy BS, Jiaquan Xu MD, Kenneth D. Kochanek, M.A. (2013). National Vital Statistics Reports. Volume 61. Number 4. U.S. Department Of Health And Human Services.
  23. Shimizu I, Matsumoto T, Suzuki N, Sagara C, Koizumi Y, Asaki T, et al. (2012). Chronic Liver Disease Develop More Slowly in Females than Males. In: Simizu I (Eds.), Preventive Female Sex Factors against The Development of Chronic Liver Disease. Japan: Bentham eBooks. pp. 3-18.
  24. Sugiyono. (2010). Metode Penelitian Kuantitatif Kualitatif dan R&D. Bandung: Penerbit CV Alfabeta Bandung.
  25. Tsao GG. (2012). Cirrhosis and Its Sequel. In: Goldman L (Eds.), Goldman's Cecil Medicine. 24th edition. Philadelphia: Elsevier. pp. 999-1007.